STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.

Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.

Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, provided business updates and preliminary financial results for the six-month period ending June 30, 2023. Clinical trials for UCART22, UCART20x22, and UCART123 are ongoing. Preclinical data on HBB gene correction and TALE Base Editors were presented. The company appointed Cécile Chartier as Director. Cash position as of June 30, 2023, was $89 million. Full financial statements for Q2 2023 will be released soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
Euronext Growth: FR0010425595 Shares and Voting Rights Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
Rhea-AI Summary
Cellectis S.A., a clinical-stage biotechnology company, will report financial results for Q2 2023 on August 3, 2023. An investor conference call and webcast will follow on August 4, 2023, providing updates on business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences earnings
-
Rhea-AI Summary
Cellectis S.A. has appointed Cécile Chartier, Ph.D., as a Director of the Company's Board of Directors. Dr. Chartier brings extensive experience in the development of cell and gene therapies, making her a valuable asset to the Company. She currently serves as Chief Scientific Officer at NextVivo, Inc. and has previously held positions at Iovance Biotherapeutics, Inc. and OncoMed Pharmaceuticals. Dr. Chartier's expertise will contribute to the advancement of Cellectis' product candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
management
-
Rhea-AI Summary
French company announces its latest shareholder information. As of June 30, 2023, the total number of shares in the capital is 55,583,768 and the total number of voting rights is 61,505,063.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

145.42M
69.31M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris